|Videos|December 28, 2017
Practical Considerations for Subcutaneous Rituximab
Advertisement
Episodes in this series
Advertisement
Related to this article
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
Advertisement
Advertisement
Trending on OncLive
1
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
2
FDA Flashback: GI Cancer Decisions and News From July 2026
3
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors
4
FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test
5